Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001140361-23-014591
Filing Date
2023-03-29
Accepted
2023-03-29 19:50:17
Documents
2
Period of Report
2023-03-22

Document Format Files

Seq Description Document Type Size
1 form3.html 3  
1 form3.xml 3 18504
2 EXHIBIT 24.1 brhc10050532_ex24-1.htm EX-24.1 9168
  Complete submission text file 0001140361-23-014591.txt   29052
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400 SOUTH SAN FRANCISCO CA 94080
Business Address
BELVIN MARCIA (Reporting) CIK: 0001970752 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37587 | Film No.: 23776827